Oxytocin Effectiveness in First Trimester Dilatation and Curettage

What Was Tested

This registered not phased trial tested Oxytocin.

It had two arms (groups): Placebo (placebo comparator) and Oxytocin (experimental).

The registry classes the interventions as drug.

More on the Plan

Study Design This study is a prospective randomized placebo-controlled double-blind trial.

Both the investigators and patients will remain unaware of the composition of the distension medium to ensure blinding.

A total of 160 patients will be included in the sample size resulting in a net total of 80 patients per group as described below.

Patients aged 18 years and older who are capable to provide informed consent.

Who Took Part

Enrollment: 160 planned participants were the target.

It was open to women only aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

The full record lists 1 inclusion and 5 exclusion criteria; among the exclusions: individual intolerance to oxytocin; mullerian anomalies; fibroid uterus.

How the Study Was Run

It was run as a randomized, parallel-group and quadruple-blind study.

The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

The Oxytocin group and the comparison group ran side by side rather than switching.

As a double-blind Oxytocin study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider, investigator and outcomes assessor.

It started in 2024-09-01 with completion listed for 2026-06.

Its stated primary purpose is prevention.

What Was Measured

Researchers chose this as the main measure: Perioperative Blood Loss Assessment (time frame: 14 days).

It also tracked 1 secondary outcome, for example perioperative complications according to the Dindo-Clavien scale.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Oxytocin in 160 people.

Its status is unknown; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Oxytocin compound page, all human trials.